Observational analysis reports 90% of patients achieve target AHI in 60 OSA patients, suggesting improved compliance with personalized treatment solutions.
Key Points
90% of patients achieved a residual AHI of less than 10 events/h after treatment with the precision-custom oral appliance.
The mean apnea-hypopnea index improved by 63% from baseline, indicating significant treatment effectiveness.
No serious adverse events were reported, highlighting the safety of the precision-custom oral appliance therapy.
All patients continued therapy at follow-up, suggesting high tolerance and compliance with the treatment.